The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Much Growth In Market Value Is Expected For The Hormone Refractory Prostate Cancer Market Between 2026 And 2030?
The market for hormone refractory prostate cancer has demonstrated rapid expansion in its size over recent years. It is projected to increase from $8.12 billion in 2025 to $8.95 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.2%. This historical growth can be ascribed to factors such as the rising incidence of advanced prostate cancer, the widespread adoption of androgen deprivation therapy, the increased availability of chemotherapy agents, the growing use of PSA-based disease monitoring, and the expansion of oncology care infrastructure.
The market size for hormone refractory prostate cancer is anticipated to experience robust growth in the coming years. It is projected to expand to $13.09 billion by 2030, with a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period is attributable to the increasing development of targeted therapies, rising clinical trial activity concerning castration-resistant prostate cancer, growing demand for personalized oncology care, an expansion of immuno-oncology pipelines, and increased healthcare expenditure on cancer treatments. Significant trends expected in the forecast period include the growing adoption of precision oncology therapies, increased use of combination drug regimens, expanding integration of biomarker-based treatment selection, a broadening of immunotherapy applications in advanced prostate cancer, and an enhanced focus on personalized treatment pathways.
Access Your Free Sample Report For In-Depth Market Analysis:
What Primary Drivers Are Shaping The Hormone Refractory Prostate Cancer Market?
The anticipated expansion of the hormone-refractory prostate cancer market is linked to an increasing commitment of resources towards cancer research. This investment encompasses financial and resource backing aimed at progressing novel methods for cancer detection, therapy, and prevention. The escalating global incidence of cancer, necessitating more potent and precise treatment options, is driving the surge in cancer research funding. Such funding stimulates breakthroughs in managing hormone-refractory prostate cancer, facilitating the development of sophisticated therapies like radioligand treatments and hormone inhibitors. Furthermore, it finances clinical trials and studies into biomarkers, thereby improving the accuracy and success rates of treatments. As an illustration, as reported by the Cancer Research Institute (CRI), a US-based nonprofit organization dedicated to advancing immunotherapy research, in August 2024, approximately $22.8 million was invested during the 2023–2024 fiscal year, supporting 64 new grants for researchers from 42 institutions across seven countries. Consequently, increased funding into cancer research is stimulating the expansion of the hormone-refractory prostate cancer market.
How Are Different Segments Classified In The Hormone Refractory Prostate Cancer Market Segment Analysis?
The hormone refractory prostate cancer market covered in this report is segmented –
1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery
2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin
2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists
3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy
4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy
5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)
What Trends Are Affecting The Growth Of The Hormone Refractory Prostate Cancer Market?
Leading firms within the hormone-refractory prostate cancer market are prioritizing the creation of advanced treatments, like intravenous radioligand therapy, aiming to enhance patient survival for those with resistant disease forms. This specific intravenous radioligand therapy employs radioactive molecules linked to ligands to pinpoint and attach to markers unique to cancer. It effectively eliminates cancer cells from within, preserving healthy surrounding tissue. As an example, in March 2025, Novartis AG, a pharmaceutical company based in Switzerland, introduced Pluvicto (lutetium Lu 177 vipivotide tetraxetan) following its approval by the Food and Drug Administration (FDA). This treatment is intended for earlier administration in patients suffering from prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have previously received an androgen receptor pathway inhibitor (ARPI) and are suitable for delaying chemotherapy. The expanded approval, stemming from the Phase III PSMAfore trial, roughly triples the number of eligible patients and demonstrated that Pluvicto lowered the risk of radiographic progression or death by 59%, while also more than doubling the median radiographic progression-free survival when compared to a switch in ARPI. Pluvicto stands as the first targeted radioligand therapy sanctioned for pre-chemotherapy use in this context, presenting a novel therapeutic choice that extends disease progression with a beneficial safety profile.
Who Are The Companies Driving Activity In The Hormone Refractory Prostate Cancer Market?
Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc
Get The Full Hormone Refractory Prostate Cancer Market Report:
Which Region Is The Largest In The Hormone Refractory Prostate Cancer Market?
North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Hormone Refractory Prostate Cancer Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Hormone Refractory Prostate Cancer Market 2026, By The Business Research Company
Benign Prostatic Hyperplasia Bph Treatment Devices And Equipment Market Report 2026
Prostate Cancer Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/prostate-cancer-diagnostics-global-market-report
Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model